<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808013</url>
  </required_header>
  <id_info>
    <org_study_id>NDB 2015-001</org_study_id>
    <nct_id>NCT02808013</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of NDS-446 in Men With Lower Urinary Tract Symptoms (LUTS)</brief_title>
  <official_title>Prospective Randomized, Double-Blind, Placebo Controlled Study of NDS-446 (500 mg/Cap) in Men 45 Years of Age or Older With Moderate to Severe Lower Urinary Tract Symptoms (LUTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naturex-Dbs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naturex-Dbs</source>
  <brief_summary>
    <textblock>
      Prospective, Randomized, Double-Blind, Placebo Controlled clinical trial to study the&#xD;
      efficacy and the safety of NDS-446 (500 mg/cap) in Men 45 years of age or older with moderate&#xD;
      to severe lower urinary tract symptoms (LUTS)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total IPSS score between baseline and 6 months</measure>
    <time_frame>6-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in IPSS subscores (Storage, Voiding, Quality of Life) between baseline and 6 months</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Improvement/Severity Score (PGIS) between baseline and 6 months</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uroflowmetry (Qmax: maximum urinary flow rate, mL/sec)</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uroflowmetry (PVR: Post Void Residual Volume, mL)</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uroflowmetry (Vol: Volume of urine voided, mL)</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual performance (SHIM: Sexual Health Inventory for Men)</measure>
    <time_frame>6-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and urine laboratory analysis and incidence of treatment emergent adverse events [Safety and Tolerability]</measure>
    <time_frame>6-month</time_frame>
    <description>Blood samples will be collected to measure:&#xD;
Prostate Specific Antigen (PSA) Hematology: CBC (complete blood count), differential; reticulocyte count, platelets Serum Chemistries: BUN (blood urea nitrogen), Creatinine, Fasting Blood Glucose, Uric acid, AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase), LDH (lactate dehydrogenase), Total and Direct Bilirubin; Total Protein, Albumin, Calcium, Magnesium, Cholesterol, Triglycerides Coagulation: PT (prothrombin time) /PTT (partial thromboplastin time)/ INR (International Normalized Ratio)&#xD;
Urine samples will be collected to measure:&#xD;
Urinalysis: Urine Protein, Glucose, Microscopic for RBCs (Red blood cell counts), WBCs (white blood cell counts)&#xD;
Assessment of adverse events: collection of adverse events on a diary and spontaneously reported adverse events (either via phone calls to the site or during the visits)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>NDS-446</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NDS-446</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NDS-446</intervention_name>
    <arm_group_label>NDS-446</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men ≥45 years of age.&#xD;
&#xD;
          2. LUTS, based on IPSS total score ≥8 and &lt;25&#xD;
&#xD;
          3. Peak urinary flow rate (Qmax) ≥4 and ≤15 mL/sec at screening&#xD;
&#xD;
          4. Post Void Residual (PVR) urine volume ≤ 200 mL at screening&#xD;
&#xD;
          5. PSA level at screening &lt; 10 ng/mL. Subjects with a PSA &gt; 4ng/mL and &lt; 10 ng/mL are&#xD;
             eligible only if prostate cancer has been ruled out&#xD;
&#xD;
          6. Subjects who understand and speak English&#xD;
&#xD;
          7. Able and willing to give informed consent and comply with all study protocol&#xD;
             procedures (diaries and other study tools).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not suitable for medical intervention (e.g., requiring TURP, etc.)&#xD;
&#xD;
          2. History of interstitial cystitis, bladder stones, urethral stricture, current&#xD;
             prostatitis, acute urinary retention requiring catheterization in the last 3 months,&#xD;
             or any other condition suspected to be the cause of LUTS other than BPH&#xD;
&#xD;
          3. Screening serum Creatinine (Cr) or liver function tests [ALT (SGPT), AST (SGOT)] &gt; 3&#xD;
             times the upper limit of normal (ULN) confirmed on a second measurement.&#xD;
&#xD;
          4. Cancer of the prostate or bladder by history or current diagnosis.&#xD;
&#xD;
          5. Prostate nodule(s) on screening digital rectal exam (DRE).&#xD;
&#xD;
          6. Prior surgical procedure of the urinary tract such as TURP, laser prostatectomy,&#xD;
             photovaporization of the prostate&#xD;
&#xD;
          7. No minimally invasive surgery to the prostate such as TUMT or TUNA within the last 6&#xD;
             months.&#xD;
&#xD;
          8. Active urinary tract infection.&#xD;
&#xD;
          9. Unstable or uncontrolled medical or psychiatric condition.&#xD;
&#xD;
         10. Abnormal screening labs &gt; 2 times the upper limit of normal (ULN) [for all parameters&#xD;
             other than those listed for exclusion criteria#3]&#xD;
&#xD;
         11. Myocardial infarction or CVA within the past 90 days.&#xD;
&#xD;
         12. Requiring ongoing administration of antibiotics, antifungals, antiviral, chemotherapy,&#xD;
             steroidal or immunosuppressive treatments.&#xD;
&#xD;
         13. Requiring chronic administration of aspirin at a dose &gt;81 mg/day.&#xD;
&#xD;
         14. Known hypersensitivity to study drug ingredient(s) or allergy to berries.&#xD;
&#xD;
         15. Use of the following medications: alpha blockers (28 days of screening), herbal or&#xD;
             nutritional BPH supplements (28 days of screening), OAB medications (28 days of&#xD;
             screening), 5 alpha reductase inhibitors (175 days of screening), PDE5 inhibitors&#xD;
             (permitted as needed for erectile dysfunction only, but not to exceed 1 dose per week&#xD;
             and not to be dosed within 5 days of a visit)&#xD;
&#xD;
         16. Use of an investigational agent (drug, biologic, device, etc.) within 30 days of&#xD;
             screening&#xD;
&#xD;
         17. Any reason or condition that in the judgment of the Clinical Investigator(s) may put&#xD;
             the subject at unacceptable risk or that may preclude the subject from understanding&#xD;
             or complying with the study's requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilie A Fromentin, Ph.D.</last_name>
    <phone>2014405000</phone>
    <phone_ext>253</phone_ext>
    <email>e.fromentin@naturex.com</email>
  </overall_contact>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

